• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, April 3

Aurobindo Pharma Ltd has announced that it has received the United States Food and Drug Administration (USFDA) approval for Cefuroxime Axetil tablets 125 mg (base), 250 mg (base) and 500 mg (base). With this oral cephalosporin approval, the company's product basket for the US market has increased to 13 (final approvals), apart from 10 tentative approvals, the company said in a press release here on Monday. The size of the generics business of Cefuroxime Axetil 125/250/500 mg is estimated at around $50 million. These tablets are indicated for the treatment of patients with infections caused by susceptible strains of designated organisms in the diseases that include pharyngitis and tonsillitis, lower respiratory tract infections, urinary tract infections and skin structure infections. Cefuroxime Axetil Tablets USP, 125 mg (base), 250 mg (base) and 500 mg (base), is the generic version of Glaxo Wellcome's Ceftin, the release said.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
JK Tyres hikes prices by 2 pc

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line